Drugs and patents in ATC class N03AD - Succinimide derivatives

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ETHOSUXIMIDE	ethosuximide
ZARONTIN	ethosuximide
MILONTIN	phensuximide
>Tradename	>Generic Name

Last updated: July 31, 2026

ATC Class N03AD covers succinimide derivatives used primarily for absence seizures. The class contains ethosuximide, methsuximide, and phensuximide. Ethosuximide is the only commercially significant product in the class in the United States. Its core composition-of-matter, formulation, and method-of-use patents expired decades ago. Current market access depends on generic manufacturing, supply reliability, regulatory compliance, and limited physician demand rather than on proprietary patent rights.

What drugs are included in ATC Class N03AD?

The World Health Organization’s ATC system assigns N03AD to succinimide derivatives, a subgroup of antiepileptic drugs.[1]

ATC code	Active ingredient	Principal use	Current commercial position
N03AD01	Ethosuximide	Absence seizures	Established generic market; U.S. oral solution and capsules available
N03AD02	Methsuximide	Refractory epilepsy, historically including absence seizures	Limited and intermittent commercial availability
N03AD03	Phensuximide	Historical anticonvulsant use	Largely obsolete or unavailable in major regulated markets

Ethosuximide is the clinically dominant N03AD product. The FDA labeling for Zarontin identifies ethosuximide for the treatment of absence seizures, also known as petit mal seizures.[2] Methsuximide has a narrower and older clinical role. Phensuximide has little current commercial relevance.

Which companies market N03AD products?

Ethosuximide manufacturers

Ethosuximide is available in multiple dosage forms, including:

250 mg capsules
Oral solution, commonly 250 mg/5 mL
Generic products supplied through U.S. and international manufacturers

The historical reference brand is Zarontin. Pfizer has been associated with the Zarontin product and reference labeling. Generic ethosuximide products are marketed by manufacturers that have obtained abbreviated new drug application approval or equivalent approval outside the United States.

The market is characterized by low unit volume compared with newer antiseizure medicines. Pediatric use and the need for an oral liquid create recurring demand for solution products, while capsules serve long-term maintenance therapy.

Methsuximide manufacturers

Methsuximide was historically marketed in the United States under the Celontin name. Its commercial position is materially weaker than ethosuximide’s. Product availability has been constrained by low demand, limited manufacturing scale, and the age of the clinical market.

Phensuximide manufacturers

Phensuximide has no meaningful current branded market in the United States. Its clinical use was displaced by newer antiepileptic drugs and by better-established alternatives for absence seizures.

What patents protect ethosuximide, methsuximide, and phensuximide?

No active U.S. patent estate materially protects the N03AD molecules or their conventional dosage forms. The relevant composition-of-matter and early clinical-use rights date to the mid-20th century and have expired.

Product	Core patent position	Current patent barrier
Ethosuximide	Historical composition and use rights expired	No meaningful active U.S. patent barrier
Methsuximide	Historical composition and use rights expired	No meaningful active U.S. patent barrier
Phensuximide	Historical composition and use rights expired	No meaningful active U.S. patent barrier

The absence of a modern patent estate is consistent with the age of the products. Ethosuximide was introduced in the 1950s, and methsuximide and phensuximide were also developed during the early era of anticonvulsant pharmacology.

The FDA Orange Book is the relevant source for patents listed against approved drug products. Current Orange Book records for the N03AD reference products do not present an active patent framework comparable with newer branded antiseizure drugs.[3]

When did N03AD products lose exclusivity?

N03AD products lost commercial exclusivity many decades ago.

Milestone	Ethosuximide	Methsuximide	Phensuximide
Initial clinical commercialization	1950s	1950s-1960s	1950s-1960s
Expected original patent expiry	Expired decades ago	Expired decades ago	Expired decades ago
Current FDA small-molecule exclusivity	None	None or not commercially relevant	None
Current Orange Book patent exposure	No material listed-patent barrier	No material listed-patent barrier	No material listed-patent barrier
Generic entry status	Established	Historically established but limited	Commercially marginal

No N03AD product has remaining new chemical entity exclusivity, orphan exclusivity, pediatric exclusivity, or other meaningful FDA exclusivity period associated with the original product.

What is the Orange Book status of ethosuximide?

The FDA lists ethosuximide products and the historical Zarontin reference product in its approved drug databases. The reference product has long been off patent, allowing generic competition.[3,4]

The commercial implications are:

Generic manufacturers do not need to wait for patent expiry.
ANDA applicants face ordinary quality, bioequivalence, manufacturing, and labeling requirements.
A formulation-specific patent strategy would require a newly developed product with clinically meaningful differentiation.
Traditional capsules and oral solutions have limited patentability after decades of use.

The Orange Book status does not eliminate regulatory barriers. Manufacturers still must demonstrate pharmaceutical quality, stability, content uniformity, dissolution performance, and, where required, bioequivalence.

Are there Paragraph IV challenges for N03AD products?

Paragraph IV litigation is not a material current feature of the N03AD market. No active listed-patent framework appears to support a conventional Paragraph IV dispute for ethosuximide, methsuximide, or phensuximide.

A generic applicant normally uses a Paragraph IV certification when it asserts that a listed patent is invalid, unenforceable, or will not be infringed. Where no relevant patent is listed, the principal certification route is generally a Paragraph III certification or a certification that no patent information is filed, depending on the product and FDA record.[5]

The practical result is that N03AD generic entry is determined by:

ANDA approval timing
manufacturing capacity
drug-shortage risk
active pharmaceutical ingredient sourcing
commercial willingness to maintain a low-volume product
state and institutional purchasing contracts

Patent litigation does not presently control market access for these drugs.

What formulations are protected by N03AD patents?

Conventional N03AD formulations have no meaningful active U.S. patent protection.

Ethosuximide capsules

Ethosuximide capsules are immediate-release dosage forms based on a long-established small molecule. No current patent barrier is associated with the conventional 250 mg capsule presentation.

Ethosuximide oral solution

The oral solution is commercially important because it supports pediatric dosing and patients who cannot swallow capsules. Its value is primarily operational rather than patent-based. Potential technical differentiation could involve:

Taste masking
Improved chemical stability
Reduced preservative burden
Unit-dose packaging
Dosing-device integration
Lower excipient-related adverse effects

These attributes could support a new formulation application only if the sponsor generated sufficient technical and regulatory differentiation. Routine reformulation would face significant obviousness and prior-art challenges.

Methsuximide capsules

Methsuximide has historically been supplied as capsules. The dosage form is old and does not present a meaningful current formulation-patent barrier.

Extended-release and alternative delivery systems

No commercially important extended-release, transdermal, injectable, implantable, or targeted-delivery N03AD product has established a competitive market. A novel delivery system could create new patent opportunities, but it would require clinical, manufacturing, and reimbursement justification in a very small therapeutic market.

How strong is the N03AD patent estate?

The patent estate is weak from a branded-product perspective and open from a generic-entry perspective.

Patent category	Estate strength	Business implication
Composition of matter	Expired	No molecule-level exclusivity
Salt or polymorph	No material current barrier	Limited scope for lifecycle protection
Conventional capsule	Weak or expired	Generic substitution is feasible
Oral solution	Weak or expired	Pediatric formulation remains commercially useful but not strongly protected
Method of use	Historical uses expired	No meaningful indication-based exclusivity
Manufacturing process	Potentially protectable only for new processes	Difficult to defend against alternative processes
Device or packaging	No established market barrier	Possible niche protection for differentiated products

The main intellectual-property risk is therefore not infringement risk. It is the cost of maintaining compliant manufacturing and supply.

What manufacturing and intellectual-property barriers affect N03AD drugs?

N03AD products have low technical complexity relative to biologics or modern modified-release products. Their manufacturing barriers are commercial and quality-related.

Active pharmaceutical ingredient supply

Ethosuximide requires a dependable API source that meets identity, assay, impurity, residual-solvent, and stability specifications. A small number of qualified suppliers can create supply concentration even when no patents restrict production.

Oral-solution manufacturing

Liquid products require validated control of:

Assay uniformity
Microbial limits
Preservative performance
Container-closure compatibility
Sedimentation or crystallization risk
Shelf-life stability

For a low-volume product, these fixed costs can discourage manufacturers from entering or remaining in the market.

Manufacturing-process patents

A manufacturer could seek process protection for a novel, lower-impurity, higher-yield, or more stable route. Such a patent would not block all ethosuximide production unless the protected process were commercially indispensable. Old compounds generally have extensive process prior art, which limits the scope and durability of new process claims.

What FDA regulatory status applies to N03AD products?

N03AD products are conventional FDA-approved small-molecule drugs, not biologics. Biosimilar regulation under the Public Health Service Act does not apply.

Regulatory issue	N03AD position
Product category	Small-molecule prescription drugs
Primary generic pathway	ANDA under Section 505(j)
Biosimilar pathway	Not applicable
Reference product	Established branded products such as Zarontin and historically Celontin
Exclusivity	Expired
Key approval issues	Bioequivalence, CMC, stability, labeling, manufacturing compliance
FDA safety authority	Ongoing postmarket surveillance and labeling control

Ethosuximide labeling includes warnings concerning hematologic effects and recommends periodic blood counts and urinalysis. These established safety requirements can affect generic labeling and pharmacovigilance obligations.[2,6]

What patent litigation and settlement agreements affect N03AD?

No material active U.S. patent litigation or settlement agreement currently shapes the N03AD market. The products predate the modern branded-generic litigation model, and there is no active Orange Book patent position comparable with protected products such as newer antiseizure drugs.

Historical product discontinuations should not be confused with patent settlements. A manufacturer may stop supplying a low-volume medicine because of economics, quality systems, API availability, or portfolio rationalization without transferring patent rights or settling Paragraph IV claims.

How does N03AD compare with newer absence-seizure drugs?

Ethosuximide remains clinically important for typical absence seizures, but the broader antiseizure market includes newer products with more substantial patent estates and wider indications.

Drug	Primary absence-seizure role	Patent position	Market profile
Ethosuximide	Targeted treatment for typical absence seizures	Expired	Low-cost generic niche
Valproate	Broad-spectrum epilepsy treatment	Core patents expired	Large generic market; broader safety considerations
Lamotrigine	Broad-spectrum treatment; selected absence-seizure use	Core patents expired	Large generic market
Levetiracetam	Broad-spectrum antiseizure treatment	Core patents expired	Large generic market; multiple dosage forms
Brivaracetam	Broad-spectrum antiseizure treatment	Later-generation patent estate	Branded and specialty market
Cenobamate	Refractory focal-onset seizures	Active modern patent estate	Branded specialty market

Ethosuximide competes on indication specificity, clinical familiarity, and low acquisition cost. It does not compete on patent-protected formulation technology or broad commercial differentiation.

What generic entry risks exist for N03AD products?

Patent-based generic-entry risk is low because the relevant patents have expired. Commercial supply risk is higher.

Generic launch scenarios

Scenario	Probability driver	Market effect
New capsule entrant	ANDA approval and adequate demand	Additional price competition
New oral-solution entrant	Manufacturing economics and pediatric demand	Improved supply resilience
Existing supplier withdrawal	Low margins or quality action	Shortage and price volatility
API disruption	Supplier concentration or compliance issue	National or regional shortage
Branded relaunch	Commercial niche strategy	Limited unless supported by formulation differentiation
Novel delivery product	Clinical and reimbursement success	Could create a new protected segment

The largest exposure is operational. A single supplier’s withdrawal can affect availability even when several approved products exist, because approved status does not guarantee active commercial distribution.

How large is the N03AD market and what is the revenue exposure?

Public financial reporting generally does not disclose N03AD revenue as a separate line item. Ethosuximide sales are small relative to broad-spectrum antiseizure drugs and are typically embedded within larger generic or specialty portfolios.

Revenue exposure is concentrated in:

Pediatric and neurology prescribing
Chronic maintenance therapy
Oral-solution demand
Hospital and pharmacy supply contracts
Regional generic distribution

For a diversified generic manufacturer, N03AD revenue is unlikely to be material on a consolidated basis. For a niche supplier, however, a single ethosuximide product can have strategic importance because low competition may support stable demand and occasional price increases during shortages.

What is the geographic coverage of N03AD products?

Ethosuximide has the broadest geographic availability, although product names, strengths, formulations, and regulatory status vary by country. Methsuximide and phensuximide have narrower availability.

Patent expiry is not the primary geographic issue. Market access depends on:

National marketing authorization
Local pharmacopoeial requirements
Reimbursement listing
Import controls
API qualification
Distributor economics
National shortage policies

Expired U.S. patents do not create automatic approval rights in Europe, Japan, Canada, or other jurisdictions. Each market requires separate regulatory authorization and supply compliance.

Key Takeaways

ATC N03AD includes ethosuximide, methsuximide, and phensuximide.
Ethosuximide is the only materially significant current product in the class.
Core composition, formulation, and method-of-use patents expired decades ago.
The FDA Orange Book does not present a material active patent barrier for conventional N03AD products.
Paragraph IV litigation and patent settlements do not currently control N03AD market access.
Biosimilar risk is irrelevant because N03AD products are small-molecule drugs.
Generic entry is legally open but commercially constrained by low demand and manufacturing economics.
Oral solution supply is strategically important, particularly for pediatric patients.
The principal business risk is shortage, API disruption, or supplier withdrawal rather than patent infringement.
Public companies generally do not report N03AD revenue separately.

FAQs

Is ethosuximide still patent protected in the United States?

No. The original ethosuximide patent rights expired decades ago. Conventional capsules and oral solutions are supplied in a generic market.

Can a company obtain a new patent for an ethosuximide formulation?

Yes, but only a technically differentiated formulation with patentable novelty and nonobviousness would have a meaningful prospect. Routine changes to excipients, concentration, or packaging would face extensive prior art.

Is methsuximide interchangeable with ethosuximide?

No. They are different active ingredients with different labeling, clinical histories, and regulatory products. Substitution requires clinical and regulatory assessment rather than automatic generic interchangeability.

Does an ethosuximide shortage create patent-based exclusivity?

No. A shortage can improve pricing or supplier leverage, but it does not create patent protection or regulatory exclusivity.

Are N03AD products eligible for biosimilar competition?

No. Ethosuximide, methsuximide, and phensuximide are chemically synthesized small molecules. Their competitors use generic-drug pathways rather than the biosimilar pathway.

References

World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: N03AD succinimide derivatives. https://www.whocc.no/atc_ddd_index/
U.S. Food and Drug Administration. (n.d.). Zarontin (ethosuximide) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information
National Library of Medicine. (n.d.). Ethosuximide drug label. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

Drugs in ATC Class N03AD

Drugs in ATC Class: N03AD - Succinimide derivatives

N03AD Succinimide Derivatives: Market Dynamics, FDA Status, and Patent Landscape